Aurora Private Wealth Inc. Takes $986,000 Position in Pfizer Inc. (NYSE:PFE)

Aurora Private Wealth Inc. bought a new position in Pfizer Inc. (NYSE:PFE - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 38,926 shares of the biopharmaceutical company's stock, valued at approximately $986,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in PFE. Norges Bank purchased a new stake in shares of Pfizer in the fourth quarter worth $2,328,986,000. Starboard Value LP bought a new position in Pfizer in the 4th quarter worth $407,730,000. Raymond James Financial Inc. purchased a new stake in Pfizer in the 4th quarter worth $274,694,000. Assenagon Asset Management S.A. raised its holdings in Pfizer by 307.5% during the first quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company's stock valued at $254,574,000 after acquiring an additional 7,581,030 shares during the period. Finally, Massachusetts Financial Services Co. MA lifted its position in shares of Pfizer by 7.5% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock valued at $2,029,604,000 after acquiring an additional 5,350,381 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Up 0.5%

NYSE PFE opened at $25.45 on Friday. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The firm has a market capitalization of $144.66 billion, a price-to-earnings ratio of 18.44, a PEG ratio of 0.92 and a beta of 0.58. The company has a fifty day moving average of $23.67 and a two-hundred day moving average of $24.84.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The firm had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. During the same period in the previous year, the company earned $0.82 EPS. The firm's revenue for the quarter was down 7.8% compared to the same quarter last year. On average, analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 6.76%. Pfizer's dividend payout ratio (DPR) is 124.64%.

Analyst Ratings Changes

Several brokerages recently issued reports on PFE. Citigroup lifted their target price on Pfizer from $23.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. UBS Group lifted their price objective on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. HSBC dropped their target price on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research report on Monday, May 19th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Finally, TD Cowen decreased their price target on shares of Pfizer from $32.00 to $28.00 and set a "hold" rating on the stock in a research note on Tuesday, April 22nd. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have given a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $28.55.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.